MyHep All (Sofosbuvir/Velpatasvir)

Introduction

MyHep All is a combination antiviral medicine used to treat chronic hepatitis C (HCV). It is effective against multiple genotypes, including 1, 2, 3, 4, 5, and 6. The medicine contains two active ingredients, Sofosbuvir and Velpatasvir, which work together to stop viral replication and help achieve a sustained virologic response (SVR), often considered a cure.

MyHep All is taken as a once-daily oral tablet, making it a convenient and effective treatment option. It has improved hepatitis C management by offering shorter treatment duration, fewer side effects, and no need for interferon therapy.

Components of MyHep All

Sofosbuvir (400 mg)

Sofosbuvir is a nucleotide polymerase inhibitor that blocks the NS5B enzyme required for replication of the hepatitis C virus. By inhibiting this enzyme, it prevents the virus from multiplying and reduces viral load.

Velpatasvir (100 mg)

Velpatasvir is an NS5A inhibitor that blocks a protein essential for viral replication and assembly. It helps stop the virus from spreading in the liver and supports viral clearance.

Mechanism of Action

Action of Sofosbuvir

Sofosbuvir inhibits the NS5B polymerase enzyme, which is necessary for viral RNA replication. This prevents the virus from making copies of itself.

Action of Velpatasvir

Velpatasvir targets the NS5A protein, which plays a key role in viral replication and assembly. Blocking this protein limits the virus’s ability to multiply.

The combination of these two drugs provides strong antiviral activity and reduces the risk of resistance, leading to high cure rates.

Indications for Use

Chronic Hepatitis C Infection

Used for adults with chronic hepatitis C infection across genotypes 1 to 6.

Treatment-Naive Patients

Effective for patients who have not received prior hepatitis C treatment.

Previously Treated Patients

Can be used in patients who did not respond to earlier therapies.

HIV Co-infection

Suitable for patients infected with both hepatitis C and HIV, under medical supervision.

Compensated Cirrhosis

Effective in patients with compensated liver cirrhosis.

Dosage and Administration

Standard Dosage

• One tablet daily (Sofosbuvir 400 mg + Velpatasvir 100 mg)
• Can be taken with or without food

Treatment Duration

• Usually 12 weeks
• May extend to 24 weeks in certain cases

Missed Dose

Take the missed dose as soon as remembered. If it is close to the next dose, skip the missed dose. Do not take a double dose.

Precautions and Warnings

Liver Function

Use with caution in patients with severe liver disease. Not recommended in decompensated cirrhosis without specialist supervision.

Drug Interactions

Avoid use with certain medicines such as rifampin, St. John’s Wort, and some anticonvulsants, as they may reduce effectiveness.

Pregnancy and Breastfeeding

Use only if clearly needed and prescribed by a doctor. Consult your healthcare provider before use.

Risk of Reinfection

Patients should avoid high-risk behaviors, as reinfection is possible even after successful treatment.

Side Effects

Common Side Effects

• Fatigue
• Headache
• Nausea

Less Common Side Effects

• Anemia
• Increased liver enzymes

Most side effects are mild and temporary.

Effectiveness and Expected Outcomes

High Cure Rate

MyHep All provides cure rates above 90% in many patients.

Sustained Virologic Response (SVR)

The goal of treatment is SVR12, meaning no detectable virus in the blood 12 weeks after completing therapy.

Improved Liver Health

Successful treatment reduces the risk of complications such as cirrhosis and liver cancer.

Conclusion

MyHep All (Sofosbuvir/Velpatasvir) is a highly effective, once-daily treatment for chronic hepatitis C. It offers high cure rates, broad genotype coverage, and a good safety profile.

For best results, patients should follow their doctor’s advice, complete the full course, and attend regular follow-ups to monitor progress and liver health.